Related Experiment Video
Updated: Jun 3, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
Debate: Lipid-lowering Therapies and Diabetes Development.
Julia Brandts1,2, Dirk Müller-Wieland3
1Department of Internal Medicine I, University Hospital Aachen, Pauwelsstraße, 30 52074, Aachen, Germany.
Current Atherosclerosis Reports
|January 8, 2025
Summary
Statins increase the risk of new-onset diabetes (NOD) in a dose-dependent manner, potentially by affecting pancreatic beta cells. Alternative therapies may offer safer options for at-risk patients.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Lipid-lowering therapies, particularly statins, are widely used for cardiovascular disease prevention.
- Emerging evidence suggests a link between statin use and an increased risk of new-onset diabetes (NOD).
Purpose of the Study:
- To review the relationship between statins and NOD risk.
- To explore the underlying mechanisms of this association.
- To compare the NOD risk of statins with other lipid-lowering agents.
Main Methods:
- Systematic review of meta-analyses and relevant genetic/experimental studies.
- Analysis of mechanisms affecting insulin secretion and beta-cell function.
Main Results:
- Meta-analyses confirm a dose-dependent increase in NOD risk with statins, especially high-intensity ones.
- Statins may impair insulin secretion via effects on G protein function, calcium signaling, and beta-cell cholesterol homeostasis.
- Unlike other LDL-lowering drugs, statins appear to have specific mechanisms contributing to NOD risk.
Conclusions:
- Statins offer cardiovascular benefits but carry an increased NOD risk, potentially due to intracellular pathways affecting liver and beta-cell function.
- Personalized treatment strategies and alternative lipid-lowering therapies may be safer for diabetic patients.
- Findings may influence future clinical guidelines and therapeutic approaches for lipid management.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
529
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
529
01:23Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K